Engflag

Vitafol-One

Quick links to important sections

Vitafol-One

Vitafol-One_ES

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitafol-One

Property Description
Active Ingredients L-methylfolate, Ferrous Fumarate (Iron), DHA, Multivitamins, Minerals
Form Soft Gel Capsule (Oral Supplement)
Pharmacological Class Dietary Supplement, Iron Products, Hematopoietic Agent
Common Use Nutritional support for women during pregnancy and lactation
Origin Synthetic and Derived Components

What Type of Supplement is Vitafol-One?

Vitafol-One is classified as a high-potency Prescription Prenatal Vitamin supplement. It is an oral combination product presented as a Soft Gel Capsule intended to provide comprehensive nutritional support for women during the periconceptional period, pregnancy, and lactation. The supplement belongs to the Dietary Supplement and Iron Products pharmacological classes. Its prescription status is a key differentiating factor, often reflecting the need for specialized, higher concentrations of essential nutrients necessary to support the elevated physiological demands of gestation, unlike standard over-the-counter options.

Key Components: Folic Acid, Iron, and DHA

The product features a comprehensive formulation of Multivitamins and Minerals, prominently including L-methylfolate, Ferrous Fumarate (Iron), and Docohexaenoic Acid (DHA). The formula utilizes L-methylfolate, the biologically active form of Folic Acid, which is readily available for the body's use and may be advantageous for individuals with common genetic variations affecting folate metabolism. Due to its bioavailability compared to the synthetic form, L-methylfolate is included to support high-quality prenatal care. The Ferrous Fumarate component, which serves as a Hematopoietic Agent, delivers Iron essential for Erythropoiesis (red blood cell production). Additionally, the DHA component, sourced from derived origins, is an Omega-3 Fatty Acid integral to the structural integrity of the nervous system.

What is the General Purpose of Vitafol-One?

The primary general purpose of Vitafol-One is to achieve Targeted Nutritional Repletion by supplementing the mother's diet with essential nutrients to support her overall health and fetal development. The comprehensive formulation supports the proper growth of the baby's brain and eyes through the provision of DHA, and contributes to the vital process of fetal neural tube development through the inclusion of L-methylfolate. The unique single Soft Gel Capsule design, combining both the multivitamin complex and the DHA, is a primary differentiating factor aimed at improving patient adherence to the once-daily regimen throughout the demanding period of pregnancy.

Regulatory References

  1. Folate - Health Professional Fact Sheet
  2. Iron - MedlinePlus

What side effects are possible with Vitafol-One?

Possible side effects and safety information

The safety profile of Vitafol-One is structured around potential adverse events related to its essential component ingredients, as documented in regulatory labeling. Standard frequency classifications (e.g., Common, Uncommon) are not formally applied to the combination product, but reported adverse events are categorized by the physiological system affected.

System-Organ Class Adverse Reactions

The most frequently reported adverse events are associated with the Gastrointestinal system, often noted as complaints or discomfort. Other systems where reactions may occur include the Dermatological system (skin ailments), the Metabolism and Nutrition system (glucose abnormalities), and the Ophthalmic system (visual problems). Allergic and idiosyncratic reactions are also possible at any dose.

Serious Adverse Reactions and Safety Constraints

The regulatory documentation highlights specific serious safety concerns, mainly tied to component risks. Accidental overdose of iron-containing products is the leading cause of fatal poisoning in children under six years of age, necessitating careful storage. Furthermore, high doses of folic acid may mask untreated pernicious anemia, allowing potentially irreversible neurological damage to progress. High intake of Vitamin D may lead to hypercalcemia, resulting in risks such as kidney stones or renal failure. Consumption of over 3 grams per day of omega-3 fatty acids may result in excessive bleeding.

Safety restrictions prohibit the use of Vitafol-One in patients with known hypersensitivity to any component, pre-existing hemochromatosis or other iron storage diseases, or untreated pernicious anemia.

Duration-Related and Population-Specific Safety

Prolonged use of iron salts is associated with the potential for iron storage disease. Caution is advised for specific populations, including patients with a known soy sensitivity, those with pre-existing hypercalcemia, or patients with an overactive thyroid. The product is generally not recommended for pediatric use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for this multivitamin and mineral product, which contains Ferrous Fumarate (Iron), mandates specific actions due to the potential for serious toxicity associated with iron overdose. Accidental overdose of iron-containing products is documented as a leading cause of fatal poisoning in children under six.

Overdose manifestations typically begin with gastrointestinal symptoms, including stomach pain, vomiting, and diarrhea, which may progress to the presence of blood. Severe, life-threatening outcomes involve multi-system organ toxicity, including the cardiovascular system (leading to shock and low blood pressure), the central nervous system (resulting in coma or convulsions), and delayed damage to the liver and kidneys.

Immediate Emergency Action

Action Regulatory Guidance
Help Seeking Call a doctor or a Poison Control Center immediately in case of accidental overdose.
Severe Symptoms Immediately call emergency services if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Official management procedures for severe iron toxicity include immediate supportive treatment to manage symptoms and, if necessary, specific medical interventions such as chelation therapy to help remove the excess iron from the body, alongside continuous observation and monitoring of vital signs.

Therapeutic Uses of Vitafol-One

Quick Facts

  • Therapeutic Domain: Nutritional support during the maternal period.
  • Core Indication: Supplementation to address nutritional requirements prior to and throughout pregnancy.
  • Postnatal Use: Provides complementary vitamins, minerals, and DHA for the postnatal period.
  • Key Contribution: Helps in maintaining adequate maternal nutrient status.

What Vitafol-One Supports: Main Uses and Benefits

Vitafol-One is a prescription prenatal supplement formulated to support the nutritional status of women planning for pregnancy, currently pregnant, or in the postnatal period, including breastfeeding. The product is indicated as a regimen to provide complementary dietary intake of essential vitamins, minerals, and the omega-3 fatty acid DHA (docosahexaenoic acid).

During this vital maternal period, the body’s nutritional needs are increased. This product contributes to maintaining adequate levels of key nutrients, such as Folic Acid, Iron, Iodine, and Vitamin D, which are considered essential for maternal well-being and fetal development.

Specifically, the inclusion of folic acid is intended to assist in the development of the fetal brain and spinal cord, particularly in the earliest stages of pregnancy. Iron serves to support increased oxygen transport required during gestation. The overall profile of the supplement is designed to offer support when dietary intake alone may be insufficient to meet the higher demands of this stage.

Eligibility and Restrictions for Use

Population Eligibility for Vitafol-One

Official regulatory information defines the eligibility for Vitafol-One based on the patient population and specific pre-existing health conditions. The primary approved users are women during the periconceptional period, throughout pregnancy, and during the postnatal period, including both lactating and non-lactating mothers.

Contraindications and Restrictions

Use of the supplement is contraindicated and absolutely prohibited for individuals with hypersensitivity to any of its components or color additives. Non-eligibility is also mandated for patients diagnosed with hemochromatosis, other iron storage diseases, or untreated and uncomplicated pernicious anemia.

Eligibility Group Regulatory Status
Pediatric Use Not recommended for use
Hypercalcemia Use with caution only
Overactive Thyroid Use with caution only

Use of the product requires caution in patients who have certain comorbidities such as hypercalcemia, conditions like hyperparathyroidism, and those who form calcium-containing kidney stones. Caution is also advised for patients with an overactive thyroid and known soy sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile identifies specific drug classes and substances that may interact with the supplement's components, including Folic Acid, Zinc, and Iodine. These include anticonvulsant medications (such as Carbamazepine and Phenytoin), Methotrexate, certain antibiotics, and anti-thyroid drugs. Interaction documentation also applies to specific supplements, such as the total daily intake of Omega-3 fatty acids and the co-administration of Calcium.

Interactions are generally classified as use-with-caution restrictions due to the potential for reduced drug exposure or additive pharmacodynamic effects. The regulatory documentation establishes constraints based on the co-administration of substances, total supplemental intake, and the pre-existing condition of hypercalcemia.

The primary constraint is a mandatory timing rule for Zinc: Zinc-containing supplements must be administered at least two hours apart from certain antibiotics to prevent the Zinc from inhibiting antibiotic absorption. High doses of Folic Acid are documented to decrease the serum levels of specific anticonvulsants and may reduce the patient's response to Methotrexate. Additive effects include the potential for Iodine to contribute to hypothyroidism when taken with anti-thyroid drugs and the risk of excessive bleeding if Omega-3 consumption exceeds 3 grams per day from all sources.

Mechanism of Action

How Vitafol-One Works

Vitafol-One is a combination formulation of specific vitamins, minerals, and Docosahexaenoic acid (DHA). Its action is mediated by the delivery and incorporation of these micronutrients into various biological systems.

Cofactor and Enzyme Signaling Modulation

The B vitamins (folate, B6, B12) and select minerals function as cofactors for specific enzymatic reactions, primarily in one-carbon metabolism. This mechanism is relevant in cascades that influence DNA synthesis, repair, and amino acid conversion, thereby modulating cellular proliferation and differentiation, particularly in systems exhibiting high tissue turnover.

Structural and Functional Cellular Support

Docosahexaenoic acid (DHA), an omega-3 fatty acid, and certain fat-soluble vitamins affect systems where lipid-based structural components dominate, such as cell membranes. DHA incorporation supports the regulation of processes driven by distinct signaling patterns, influencing the biophysical properties and functional responses of cellular membranes.

Erythropoiesis and Mineral Homeostasis

Iron, copper, and select B vitamins engage mechanisms that regulate the processes of hemoglobin production and red blood cell formation (erythropoiesis). Concurrently, Vitamin D and other minerals modulate key pathways associated with hormone-mediated regulation of calcium and bone metabolism, acting within domains involving receptor-mediated signaling to mediate cellular signal transduction involved in mineral deposition and turnover.

Dosage and Administration Information

Official Administration Guidelines for Vitafol-One

This section outlines the administration procedure for Vitafol-One softgel capsules. Vitafol-One is intended for use in adults for supplementation prior to conception, throughout pregnancy, and during the postnatal period for both lactating and non-lactating mothers, and is not for pediatric use.

Administration Protocol

Guideline Official Instruction
Route By mouth (Oral softgel capsule).
Dosing One softgel capsule daily, or as directed by a healthcare professional.
Frequency Once daily.
Timing Not explicitly mandated, but may be taken with or without food. If stomach upset occurs, taking it with food is advised.
Preparation The softgel capsule must be swallowed whole with water. Do not crush, chew, or split the capsule.
Use Context For use before, during, and after pregnancy.

Missed Dose Instructions

If a dose of Vitafol-One is missed, the general guideline is to take the missed dose as soon as you remember. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Patients must not take double or extra doses to compensate for a missed one.

Procedural Summary

The full procedure requires the patient to orally ingest one softgel capsule per day using water, following a consistent daily pattern throughout the preconception, gestational, and postnatal phases. The instruction sequence is designed around a non-complex, single-unit daily intake to maintain continuity of supplementation.

Recent Clinical Evidence

The research surrounding Vitafol-One, as a combination prescription prenatal supplement, primarily focuses on the extensive clinical data available for its essential components: folate/L-methylfolate, Iron, and DHA (docosahexaenoic acid). Research exists for these nutrients from large-scale Randomized Controlled Trials (RCTs) and systematic reviews, which includes studies examining outcomes related to the maternal and fetal periods.

Evidence on Folic Acid and Prevention of Neural Tube Defects

Research explored the role of folic acid supplementation during the critical weeks around conception and the first trimester. Studies examined patterns related to the rate of Neural Tube Defects (NTDs) in women planning pregnancy. These findings have contributed to the broader evidence landscape related to folate supplementation. However, data are still emerging for the specific association between the L-methylfolate form and NTD outcomes across large populations compared to synthetic folic acid.

Studies on Maternal Status and Neonatal Birth Outcomes

RCTs were used to evaluate the multivitamin and Iron complex against comparison groups, such as those receiving only Iron and Folic Acid (IFA). Studies monitored maternal blood status biomarkers and neonatal outcomes like birth weight and preterm birth. Findings were associated with differences in the incidence of low birth weight infants in certain populations, but research comparing the full multivitamin to IFA alone reported mixed evidence for outcomes like preterm birth.

Research on DHA and Fetal Neurodevelopment

This research uses Double-Blind RCTs to study the relationship between maternal DHA supplementation and measures of infant and child cognitive, developmental, and visual acuity scores. Findings from multiple large RCTs were mixed or inconsistent regarding long-term cognitive outcomes (like overall IQ scores). Certainty remains low for the definitive long-term effects on global intelligence measures, as evidence quality varies.

Research Gaps and Areas of Uncertainty

Long-term follow-up remains an area of ongoing study. While research explored outcomes for women planning conception and compared multivitamin regimens, the follow-up durations were limited in many studies. The data for certain groups remain insufficient to draw broad conclusions, and research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

  1. The role of omega-3 fatty acids in child development (OCL Journal Review)
  2. Label: PRENATAL VITAMINS PLUS tablet (NIH DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Vitafol-One (FAQ)

Q: Is Vitafol-One different from a regular multivitamin?

A: Vitafol-One is formally classified as a Prescription Prenatal Vitamin supplement. The prescription classification indicates it is intended for use under professional guidance.

Q: What is the source of the DHA in Vitafol-One?

A: According to the official product composition, the Docosahexaenoic acid (DHA) component in the supplement is sourced from natural algal oil.

Q: Does Vitafol-One interact with common medications like antacids or thyroid hormones?

A: Regulatory documents indicate that potential interactions are documented with several classes of medications. These include certain antacids, some antibiotics, thyroid hormones, and the blood thinner warfarin, among others.

Q: What are the specific ingredients in Vitafol-One that may cause a reaction in people with soy sensitivity?

A: The product's inactive ingredients include Soybean Oil and Soy Lecithin. The official labeling explicitly includes a warning, stating: Contains: Soy.

Q: Does the iron in Vitafol-One sometimes cause or contribute to constipation?

A: Regulatory documents note that adverse events are most frequently associated with the Gastrointestinal system, often categorized as complaints or discomfort. Gastrointestinal upset is a common effect of iron-containing supplements.

Q: Does Vitafol-One have the potential to interact with blood thinners like Warfarin?

A: Official drug information indicates that the supplement is known to potentially interact with certain medications, including the blood thinner warfarin.

Q: Is it common to feel nauseous after taking Vitafol-One?

A: Official information indicates that adverse events are most frequently associated with the Gastrointestinal system. These may include complaints or discomfort, which are frequent occurrences with iron-containing products.

Q: Are there any known issues with taking Vitamin D in Vitafol-One if a person has certain thyroid conditions?

A: Official product information documents that caution is required for use in patients with an overactive thyroid (hyperthyroidism). Caution is also advised regarding high intake of Vitamin D due to the risk of hypercalcemia (excessive calcium in the blood).

Q: Is a change in stool color, such as to green or black, a known expected occurrence with Vitafol-One?

A: Yes, regulatory documents indicate that stools commonly change color when vitamin and mineral supplements are being taken. This is often an expected occurrence.

Q: Is Vitafol-One suitable for women who have known allergies to fish?

A: The official product description indicates that the supplement is suitable for use by women including individuals with known allergies to fish. The DHA component is sourced from algal oil.

Q: Is it necessary to continue taking Vitafol-One if I follow a very healthy and balanced diet?

A: Official drug information states that vitamin and mineral supplements do not replace the need for good nutrition from a balanced diet. The product is intended as a supplement to the diet.

Q: Does Vitafol-One contain Vitamin A (retinol)?

A: The composition lists Vitamin A. It is specifically included in the form of beta carotene at 330 mcg RAE, which is a precursor that the body converts into Vitamin A.

Q: What are the common benefits or uses listed for the iodine component of Vitafol-One?

A: Vitafol-One is generally indicated as a combination product to provide overall vitamin, mineral, and omega-3 fatty acid supplementation. The combination is indicated to provide supplementation throughout the periconceptional, pregnancy, and postnatal periods.

Q: What is the significance of the iron in Vitafol-One being described as 'gentle on the stomach' in some descriptions?

A: The iron component is specifically listed as a polysaccharide iron complex, a type of iron salt. Iron supplements generally are associated with gastrointestinal system complaints.

How should Vitafol-One be stored and disposed of?

Storage and Disposal Requirements

Vitafol-One softgel capsules must be stored at controlled room temperature, specifically between 15 C to 30 C (59 F to 86 F). The product must be protected from excessive heat, light, and moisture to ensure stability.

Due to the inclusion of iron, a critical child-safety mandate requires the product be kept out of the reach of children to prevent accidental overdose, which is a leading cause of fatal poisoning in young children. The capsules are supplied in child-resistant blister cards and must be stored in this original packaging.

Official labeling does not provide specific household disposal instructions. Unused or expired Vitafol-One must be disposed of in accordance with applicable local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vitafol-One found in:

A-Z Index: